Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease
Authors not listed
Vielight Inc. · 2019
Abstract
The active Neuro RX Gamma device uses non-invasive near-infrared energy delivered to the brain with the intention to improve cognitive functioning and quality of life in patients with moderate to severe Alzheimer's Disease. Treatment will occur at home-based treatment sessions with the device.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2019). Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease. <em>Vielight Inc.</em>. https://clinicaltrials.gov/study/NCT03484143
Vancouver
Anonymous. Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease. Vielight Inc.. 2019.
BibTeX
@misc{anon2019Vielig,
title = {Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease},
author = {Anonymous},
journal = {Vielight Inc.},
year = {2019},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Edinburgh Research Explorer 2011
Preprint · OA
Dual Tasking and Memory Binding in Alzheimer’s Disease
Hospices Civils de Lyon 2007
Open access · US-GOV
Clinical Trial on Cognitive, Behavioural, Quality of Life and Medico-economic Benefits of Hearing Aids in Alzheimer Disease Patients Suffering From Presbycusis
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only
Alzheimer's disease
Turku University Hospital 2019
Open access · US-GOV
Correlation of Musicality and Cognitive Skills in Persons With Alzheimer´s Disease
University of Tennessee Medical Center 2022
Open access · US-GOV